GLPwatch
Papers (10401)
Page 59 of 174, ranked by citation count.
- The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
- Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis.
- Exenatide and renal failure.
- Liraglutide for the treatment of type 2 diabetes: a clinical update.
- Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
- Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
- Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
- Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
- Perspectives in weight control in diabetes - Survodutide.
- Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.
- Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion.
- Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.
- Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.
- Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
- Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
- Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
- Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
- Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
- Dulaglutide: A Review in Type 2 Diabetes.
- Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
- Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
- Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
- Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
- Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway.
- Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.
- Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
- Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
- Potential use of exenatide for the treatment of obesity.
- Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.
- Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.
- The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
- The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.
- Antidepressant activity of anti-hyperglycemic agents in experimental models: A review.
- Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux.
- Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis.
- Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis.
- Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.
- Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
- Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
- Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
- Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.
- Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
- Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
- Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
- Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease.
- Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
- Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
- A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
- Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.
- Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
- Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.
- Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.
- Discovery of dual-action membrane-anchored modulators of incretin receptors.
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
- Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.
- GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.
- Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.